2019
Identification of a T follicular helper cell subset that drives anaphylactic IgE
Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, Joseph J, Gertie JA, Xu L, Collet MA, Grassmann JDS, Simoneau T, Chiang D, Berin MC, Craft JE, Weinstein JS, Williams A, Eisenbarth SC. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science 2019, 365 PMID: 31371561, PMCID: PMC6901029, DOI: 10.1126/science.aaw6433.Peer-Reviewed Original ResearchConceptsInterleukin-4B cellsFollicular Helper Cell SubsetsLow-affinity IgEFollicular helper cellsAllergen-specific IgEHelper cell subsetsIsotypes of antibodiesAlternative therapeutic targetsTranscription factor Bcl6Anaphylactic IgECytokine profileIgE productionCell subsetsHelper cellsImmunoglobulin ETherapeutic targetIgEAnaphylaxisAllergensCellular mechanismsRare populationCellsMiceGATA3
2017
Notch signaling and progenitor/ductular reaction in steatohepatitis
Morell CM, Fiorotto R, Meroni M, Raizner A, Torsello B, Cadamuro M, Spagnuolo G, Kaffe E, Sutti S, Albano E, Strazzabosco M. Notch signaling and progenitor/ductular reaction in steatohepatitis. PLOS ONE 2017, 12: e0187384. PMID: 29140985, PMCID: PMC5687773, DOI: 10.1371/journal.pone.0187384.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsDuctular reactionRole of NotchMCD diet-fed miceMethionine-choline deficient (MCD) dietHepatic progenitor cell activationPrimary hepatic stellate cellsChronic liver diseaseDiet-fed miceTGF-β1 expressionAlternative therapeutic targetsTGF-β1 treatmentProgenitor cell activationNotch-1 activationLiver injuryMCD dietLiver diseaseFibrosis progressionNotch signalingDR responseLiver repairBSEP expressionHepatocyte cell lineLiver cancerAAV8-TBGColony Lysate Arrays for Proteomic Profiling of Drug-Tolerant Persisters of Cancer Cell
Kume K, Nishizuka SS. Colony Lysate Arrays for Proteomic Profiling of Drug-Tolerant Persisters of Cancer Cell. Analytical Chemistry 2017, 89: 8626-8631. PMID: 28753272, DOI: 10.1021/acs.analchem.7b01215.Peer-Reviewed Original ResearchConceptsDrug-tolerant persistersCancer cellsTranscription factorsProteomic profilingProteomic profilesLevels of proteinIndividual coloniesProtein array systemNumber of assaysSingle cellsProtein levelsCritical mechanismFunctional informationAlternative therapeutic targetsProteinTherapeutic targetFunctional heterogeneityCellsInitiation of relapseProfilingPersistersAgarose gelOct4ASTAT3Colonies
2008
Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome
Huang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931-936. PMID: 18753978, DOI: 10.2310/jim.0b013e318182080a.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolCoronary artery diseaseMetabolic syndromeLipoprotein cholesterolArtery diseaseMS patientsTherapeutic targetCross-sectional chart reviewLow-density lipoprotein cholesterolNon-HDL levelsCardiovascular risk factorsDensity lipoprotein cholesterolPublic hospital patientsAlternative therapeutic targetsCritical therapeutic targetExcessive hypertriglyceridemiaChart reviewLow HDLTotal cholesterolLDL cholesterolTriglyceride levelsRisk factorsHospital patientsHigh prevalencePatientsNon-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome
Huang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931. DOI: 10.231/jim.0b013e318182080a.Peer-Reviewed Original ResearchNon-HDL cholesterolCoronary artery diseaseMetabolic syndromeLipoprotein cholesterolArtery diseaseMS patientsTherapeutic targetCross-sectional chart reviewLow-density lipoprotein cholesterolNon-HDL levelsCardiovascular risk factorsDensity lipoprotein cholesterolPublic hospital patientsAlternative therapeutic targetsCritical therapeutic targetExcessive hypertriglyceridemiaChart reviewLow HDLTotal cholesterolLDL cholesterolTriglyceride levelsRisk factorsHospital patientsHigh prevalencePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply